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The present report identifies indole-3-ethyl isothiocyanate NB7M as a potent cytotoxic agent with selective activity against cell lines
derived from various tumour types. Ovarian cancer cell lines showed sensitivity to NB7M (60–70% cytotoxicity at 2.5mM), in contrast
to control cells (TCL-1 and HTR-8; IC50 B15mM). In a screen performed by the National Cancer Institute (NCI) (NCI60 cancer cell-
line assay) NB7M (NSC746077) reduced growth up to 100% with an IC50 between 0.1 and 10mM depending on the cell line studied.
Using SKOV-3 ovarian cancer cells as a model, mechanisms of cytotoxicity were analysed. NB7M caused hallmarks of apoptosis such
as PARP-1 deactivation, chromatin condensation, DNA nicks, activation of caspases-9, -8, -3, loss of mitochondrial transmembrane
depolarisation potential and upregulation of pro-apoptotic mitogen activated protein kinases (p38, SAP/JNK). NB7M downregulated
phosphorylation of prosurvival kinases (PI-3K, AKT, IKKa), transcription factor NF-kB, and expression of DNA-Pk and AXL receptor
tyrosine kinase. Subcytotoxic doses of NB7M inhibited DNA synthesis, caused G1-phase cell-cycle arrest and upregulated p27
expression. The present report suggests that NB7M is a selective cytotoxic agent in vitro for cell lines derived from ovarian and certain
other tumours. In addition, NB7M acts as a growth/cell-cycle-suppressing agent and may be developed as a potential therapeutic drug
to treat ovarian cancer.
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In 2007 in the United States 1444920 new cancer cases were
diagnosed and 553888 patients died of cancer. Ovarian cancer
is the leading cause of death from gynaecological malignancies
and ranks second among newly diagnosed gynaecological cancers
in the United States (Heintz et al, 2003; American Cancer Society,
2007). Although most patients (70–80%) initially respond to
cytoreductive surgery and adjuvant paclitaxel and platinum-based
chemotherapy the majority will experience disease recurrence
(McGuire et al, 1996; Piccart et al, 2000). Re-treatment with a
platinum-based drug is possible for some women the response
rate to current second-line or third-line (after interim
non-platinum therapy) chemotherapy is below 33% due to the
rise of resistance to such drugs (McGuire and Ozols, 1998;
Leitao et al, 2003; Lamberth et al, 2004; Ott and Gust, 2007).
Therefore, the development of novel chemotherapeutics with
increased activity and alternative modes of action to treat such
tumours, instead of or in addition to or after platinum therapy, is
desired.
Naturally occurring isothiocyanates (ITC) such as BITC, PEITC
and sulforaphane have been shown to inhibit chemically induced
tumorigenesis in animal models in the lung, stomach, colon, liver,
oesophagus, bladder and mammary glands (Conaway et al, 2002).
Mechanisms of ITC activity in cancer cells, such as induction of
G2/M cell-cycle arrest, and apoptosis (Singh et al, 2004),
suppression of angiogenesis with the disruption of microtubulin
polymerisation and mitotic progression of endothelial cells
(Jackson et al, 2007; Xiao and Singh, 2007), release of reactive
oxygen species and disruption of mitochondrial membrane
depolarisation have been described (Xiao et al, 2006). Isothiocya-
nates were shown to be substrates for human glutathione
transferases (Kolm et al, 1995). In addition to various naturally
occurring ITCs, synthetic ITCs such as E-4IB have been
discovered, which sensitised ovarian cancer cells to cisplatin-
induced apoptosis by affecting signalling pathways (Bodo et al,
2006).
In an initial attempt to design a more potent ITC class of
antitumour agents, we recently screened novel indolyl ethyl ITCs
for enhanced anticancer cell activity (Singh et al, 2007). 7Me-IEITC
(methyl substitution at C7 of the indole moiety) is a key
representative of this new generation of ITC with increased
potency as compared to various naturally occurring ITCs such as
BITC (Kalkunte et al, 2006), PEITC (Satyan et al, 2006) and
sulforaphane (Singh et al, 2004). The mechanisms linked to this
selective cytotoxicity include induction of apoptosis, alteration of
mitogen activated protein kinase (MAPK) signalling and cell-cycle
inhibitory effects by 7Me-IEITC in both high-risk neuroblastoma
(Singh et al, 2007) and platinum-resistant ovarian cancer cells
(Singh et al, 2008).
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sThe primary objective of this study was to further optimise the
structural attributes of 7Me-IEITC (Figure 1A). The rationale of
adding a tert-butyl carbamate group (converting the compound
into NB7M; Figure 1A) was to protect the amino group in the hope
of increasing the bioavailability as the lipophilic protection of a
nitrogen atom in various anticancer drugs enhances tissue
permeability (Serova et al, 2007). In a recent study, we reported
an increased cytotoxicity and rapid induction of apoptosis by
NB7M in nervous system cancer cells in vitro (Brard et al, 2008). In
the present study, we (1) compared the cytotoxic effects of NB7M
on ovarian and other tumour-derived cell lines, (2) identified the
mechanisms of programmed cell death of SKOV-3 cells induced by
NB7M (3) analysed the expression of key MAPKs and other
prosurvival markers and (4) reported inhibitory effects of
subcytotoxic doses of NB7M on cell-cycle progression of SKOV-3
cells substantiated by studies on the expression of check-point
regulators of the cell cycle.
MATERIALS AND METHODS
Compound
Details to the synthesis and structural characterisation of NB7M
and the standardised NCI60 cancer cell-line in vitro assay are
described in the Supplementary Information section. The purity
and stability of NB7M was determined by high performance liquid
chromatography. Purity of NB7M was 98%; NB7M showed stability
in solution for 72h at RT and of more than 12 weeks (period of
investigation) at  201C.
Cell culture
Cell lines SKOV-3, OVCAR-3 (human ovarian epithelial adeno-
carcinoma), PC-3 (human prostate adenocarcinoma), BxPC-3
(human pancreatic adenocarcinoma) and A-431 (human epider-
moid skin carcinoma) were obtained from American Type Culture
Collection (Manassas, VA, USA). TCL-1 (human immortalised
retroviral large T-antigen transfected trophoblasts) and HTR-8/
SVneo (first-trimester cytotrophoblasts with extended lifespan)
were kindly provided by Dr Surendra Sharma, Providence, RI,
USA. All cells were seeded at 5 10
5 per flask and cultured to
B80% confluency in T75 cell culture flasks (Corning, New York,
NY, USA) in DMEM or RPMI (Gibco, Rockville, MD, USA)
supplemented with 10% fetal bovine serum (Atlanta Biologicals,
Lawrenceville, GA, USA), 100Uml
 1 penicillin and 100mgml
 1
streptomycin at 371C, 5% CO2, in a humidified incubator.
Cell viability assay
Viability of cells was determined by the 96
sAqueous-One-Solution
Assay (Promega, Madison, WI, USA) (Malich et al, 1997). For
assays with inhibitors (p38/SB203580, caspase-3/Z-DEVD-FMK,
Calbiochem, La Jolla, CA, USA) cells were pre-incubated with
40mM inhibitor for 2h before drug addition. The assay was carried
out as described previously (Lange et al, 2007); data are expressed
as the mean of the triplicate determinations (X±s.d.) of a
representative experiment in % of absorbance of samples with
untreated cells (100%).
Mitochondrial transmembrane depolarisation potential
Cells (1 10
6) were seeded in a 100mm
2 Petri dish in DMEM
complete media and incubated for 24h. Media was removed and
replenished with fresh media containing 2mM NB7M for 12 or 24h.
The test was carried out as described previously (Singh et al, 2008).
Ten thousand cells were analysed for each sample.
Morphological studies
Cells were seeded into a Lab-Tek Chamber Slide System. (Nalge
Nunc., Int., Naperville, IL, USA) at a concentration of 1 10
4 per
chamber in complete medium, incubated overnight, and treated
for 24h with 2mM NB7M (BIC50)a t3 7 1C, 5% CO2. The test was
carried out as described previously (Lange et al, 2008). Repre-
sentative images were taken with an inverted microscope (Nikon
Eclipse TE2000-E fitted with a cooled CCD camera) and  20
objective.
Cell proliferation assay
Cell proliferation was determined by a BrdU assay (Roche Applied
Science, Indianapolis, IN, USA) measuring the incorporation of the
pyrimidine analogue, 5-bromo-20-deoxyuridine (BrdU) during
DNA synthesis. Briefly, cells (5 10
3) were plated into 96-well flat
bottom plates (Corning Incorporated, Corning, NY, USA) and
allowed to attach overnight before treatment with NB7M (results
section) for 42h in complete medium. The assay was carried out as
described previously (Lange et al, 2008). Experiments were
performed in triplicates; data are expressed as mean of triplicate
determinations (X±s.d.) of a representative experiment in % of
absorbance of samples with untreated cells (100%).
Cell-cycle analysis (by FACS)
Cell-cycle analysis and quantification of apoptosis were carried out
by flow cytometry. Cells were seeded into 100mm
2 tissue culture
dishes (7.5 10
5 cells per dish, Corning Incorporated), allowed to
attach overnight and treated in complete medium under cell
culture conditions with 2mM NB7M for 24 or 48h. The test was
carried out as described previously (Lange et al, 2008). Ten
thousand events were analysed for each sample. Appropriate
gating was used to select the single-cell population. The same gate
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Figure 1 Design concept and cytotoxicity of indolyl ethyl isothiocyanate
NB7M. (A) Synthesis and structure of 7Me-IEITC derivative NB7M. (see
Materials and Methods; Supplementary Information). (B) Comparative
analysis of the cytotoxic effect of NB7M in various human cancer and
control cell lines. SKOV-3, OVCAR-3 (ovarian epithelial adenocarcinomas),
PC-3 (prostate adenocarcinoma), BxPC-3 (pancreatic adenocarcinoma),
A-431 (epidermoid carcinoma), HeLa (endometrial), TCL-1 (trophoblasts)
and HTR-8 (first-trimester cytotrophoblasts) human cell lines were treated
with various concentrations (0–20mM) of NB7M for 48h. The MTS viability
assay was carried out as described (Materials and Methods). Experiments
were performed in triplicates; data are expressed as the mean of the
triplicate determinations (X±s.d.) of a representative experiment in % cell
viability of samples with untreated cells (100%).
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swas used on all samples, ensuring that the measurements were
made on a standardised cell population.
TUNEL assay
DNA fragmentation was detected by terminal deoxynucleotidyl
transferase-mediated dUTP nick-end labelling (TUNEL), using the
DeadEndt Fluorometric TUNEL System assay (Promega, Madi-
son, WI, USA). Briefly, cells (5 10
3) were plated into 96-well flat
bottom plates (Corning Incorporated) and allowed to attach
overnight before treatment with 2mM NB7M or 25mM actinomycin
D for 24h in fresh complete medium. The assay was carried out as
described previously (Lange et al, 2008). All experiments were
performed in triplicate.
Western blot analysis
Cells were seeded in 100mm
2 tissue culture dishes (5 10
5 cells
per dish) and cultured to B80% confluency. Cells were treated
with or without 2mM NB7M for various lengths of time (result
section). Polyacrylamide gel electrophoresis and immunoblotting
were carried out as described previously (Lange et al, 2008).
Primary antibodies (Cell Signaling Technology, Beverly, MA, USA)
were diluted 1:1000 in PBST/5% BSA. Bands were visualised using
horseradish peroxidase-conjugated secondary antibodies (Amer-
sham-Pharmacia Biotech, Piscataway, NJ, USA), followed by
enhanced chemiluminescence (Upstate, Waltham, MA, USA) and
documented autoradiography (F-Bx810 Film, Phenix, Hayward,
CA, USA).
RESULTS
NB7M shows differential effects on the viability of various
human cancer cell lines
In an initial approach to analyse the effects of NB7M (Figure 1A)
on ovarian cancer cells, we performed a cytotoxicity assay
(Figure 1B) using SKOV-3 and OVCAR-3 (human platinum-
resistant ovarian epithelial adenocarcinoma) cell lines in compa-
rison to adenocarcinoma cell lines from different tissues (e.g.,
BxPC-3, pancreatic; PC-3, prostate). Furthermore, we tested the
effect of NB7M on A-431 cancer cells (human epidermoid) and
immortalised cell lines with primary features (TCL-1, trophoblasts;
HTR-8, first-trimester cytotrophoblasts).
NB7M proved to be highly and dose-dependently cytotoxic for
all five cancer cell lines studied, including ovarian cancer cell lines
SKOV-3 and OVCAR-3 (60–70% cytotoxicity at 2.5mM)
(Figure 1B). In contrast, TCL-1 and HTR-8 (trophoblasts) were
not affected at 5mM NB7M. As these control cell lines possess a
similar metabolic rate as cancer cells in this screen, NB7M
apparently showed selective cytotoxicity against cancer-derived
cells. To further evaluate the tumour-type selectivity of NB7M, the
effect of this compound at 10mM was screened in an NCI60 cell line
growth/viability assay (http://dtp.nci.nih.gov/screening.html,
Figure 2A). NB7M at 10mM proved to significantly reduce the
viability of colon cancer cells (COLO205, HCT-116, HCT-15, KM12
and SW620), breast cancer (NCI/ADR-RES, MCF7), ovarian cancer
(IGROV1, OVCAR-3, OVCAR-8), leukaemia (CCRF-CEM, HL-60,
K-562, MOLT-4), renal cancer (ACHN, CAKI-1, SN12C, TK-10),
melanoma (LOX IMVI, M14, MALME-3M, SK-MEL-2, SK-MEL-
28), prostate (DU145) and non-small lung cancer cells (NCI-H23)
cells. In contrast, several non-small lung cancer cell subtypes
(EKVX, NCI-H322M and NCI-H226) and a breast cancer cell line
(BT-549) were resistant to NB7M treatment (Figure 2A). In the
same assay the dose-dependent effect of various concentrations of
NB7M (10nM–100mM) on a panel of ovarian cancer cell lines was
compared (Figure 2B). The growth of IGROV1, OVCAR-3,
OVCAR-5 was highly affected by 10mM of the drug (as shown for
OVCAR-3 in the cytotoxicity assay performed in our laboratory)
and OVCAR-8 and OVCAR-4 responded strongly to treatment,
whereas SKOV-3 revealed less but still significant reduction in
growth compared to the other five lines tested by the National
Cancer Institute (NCI). Taken together, the NCI screen (http://
dtp.nci.nih.gov/screening.html) and our cytotoxicity assays
suggest NB7M to be highly and specifically detrimental to cell
lines derived from certain tumour types, including ovarian cancer,
but less effective against other tumour types and marginally
cytotoxic for control cell lines (e.g., TCL-1, HTR-8; Figure 1B and
MRC-5 fibroblasts, Singh et al, 2008).
NB7M affects the mitochondrial membrane potential of
SKOV-3 and causes morphological hallmarks of apoptosis
To understand the mechanism involved in the cellular response to
NB7M treatment, we examined the mitochondrial transmembrane
depolarisation potential (DYm) of SKOV-3 cells by flow cytometry.
NB7M at a concentration of 2mM caused a rapid loss of DYm (29%
loss within 12h; 44% within 24h) in SKOV-3 cells (Figure 3A).
NB7M showed similar reductions in the DYm of SMS-KCNR, a
chemotherapy-resistant neuroblastoma cancer cell line (Brard
et al, 2008). Loss of DYm due to chemical agents has been reported
to be an indicator of onset of early apoptotic events (Petit et al,
1995).
In addition, treatment of SKOV-3 cells with NB7M resulted in
drastic morphologic changes. Untreated cells or cells treated for
24h with 2mM NB7M after fixation and chromatin staining with
DAPI were analysed by light and fluorescence microscopy. The
population of untreated cells showed a homogenous morphology
with nuclei lightly and evenly stained by DAPI (Figure 3B, no
drug). In contrast, after treatment with NB7M (2mM) only B20%
of cells appeared unaffected, whereas the majority of cells
(Figure 3B) showed densely stained nuclear granular bodies of
highly condensed chromatin (‘apoptotic bodies’), a classic hall-
mark of apoptosis (Earnshaw, 1995).
Induction of apoptosis in SKOV-3 ovarian cancer cells by
NB7M
We analysed the activation of cellular markers that are character-
istic of apoptosis by immunoblotting. Apoptosis is executed by
caspases; initiator caspases (such as caspases-2, -8, -9 and -10)
once activated, cleave and activate downstream effector caspases
(such as caspases-3, -6 and -7), which are responsible for the
cleavage of many intracellular proteins, leading to the morpholo-
gical and biochemical changes associated with apoptosis (Thorn-
berry and Lazebnik, 1998; Salvesen and Abrams, 2004). NB7M
treatment of SKOV-3 cells resulted in the activation/cleavage of
initiator caspases-8 and -9 (within 1–6h) followed by enhanced
upregulation of executioner caspase-3 within 18h (reaching
maximal activation at 36h) (Figure 3C). The activation of
proteolytic caspases following drug exposure resulted in the
cleavage of PARP-1 (Figure 3C). PARP, a 116kDa nuclear poly
(ADP-ribose) polymerase, is involved in DNA repair (Satoh and
Lindahl, 1992), and cleavage of PARP facilitates cellular disas-
sembly and serves as a marker of cells undergoing apoptosis
(Oliver et al, 1998). The proof that reduction of SKOV-3 viability
by NB7M is a direct consequence of the induction of apoptosis is
shown in Figure 3D. We used caspase-3 or -9 inhibitors, which
were added to the viability assay 2h before and during the
treatment with NB7M. Cytotoxicity of NB7M (at 1mM) was reduced
by B60% following addition of the caspase-3 inhibitor and by
B35% following inhibition of caspase-9.
A TUNEL assay, a common method for detecting DNA
fragmentation resulting from apoptotic signalling cascades, was
carried out. The assay relies on the presence of nicks in the DNA of
apoptotic (and necrotic) cells, which can be identified by a
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sterminal transferase that catalyses the addition of labelled dUTP.
SKOV-3 cells were treated with either 2mM of NB7M or 25mM of
actinomycin D (positive control for drug-induced DNA fragmen-
tation) for 48h. Nuclei were counterstained with propidium iodide.
TUNEL-positive nuclei were identified by yellow spots, resulting
from an overlay of the image with apoptotic staining (FL-dUTP,
green) and nuclear staining (Pi, red). As shown in Figure 3E, a
significant number of cells after NB7M treatment were TUNEL-
positive indicating fragmented DNA.
NB7M treatment causes MAPK activation and suppression
of prosurvival markers in SKOV-3 ovarian cancer cells
To define key signalling responses of SKOV-3 cells to treatment
with NB7M, we analysed the expression and activation/phosphory-
lation of cellular markers involved in prosurvival or pro-apoptotic
signalling. Immunoblotting of PAGE-separated cellular lysates
revealed that NB7M (at 2mM) caused a rapid, strong, and sustained
activation of p38 and JNK MAPK (Figure 4A). Both MAPKs are
crucial factors in signalling cascades responding to inflammatory
cytokines, stress, UV light, osmotic shock, cytotoxic drugs and
diverse pro-apoptotic stimuli (Pearson et al, 2001). Upregulation
of activated p38 and JNK MAPKs resulted in slight downregulation
of the basal level of inactive JNK and p38 (Figure 4A). In addition,
expression of the phosphorylated/activated form of ERK1/2 in
SKOV-3 was downregulated upon NB7M treatment (2mM), whereas
inactive ERK1/2 remained at high level in untreated or treated
SKOV-3 cells. Both ERK 1 and 2 (p44 and p42 MAPKs) generally
participate in a protein kinase cascade that plays a critical role in
the regulation of cell growth and differentiation and can be found
activated in their role as survival factors as well as in apoptotic
events (Pearson et al, 2001; Ahmed-Choudhury et al, 2006).
We directly addressed the role of p38 activation in the lethal
response of SKOV-3 cells to NB7M by performing the viability
assay in the presence of MAPK inhibitors (p38/SB203580,
p38/SB202190 and negative control, SB202474, Figure 4B). In-
hibitors (40mM) were added to the viability assay 2h before and
during the treatment with NB7M (1.5 or 3mM). A significant
suppression of NB7M cytotoxicity was achieved by interfering with
p38 MAPK signalling (B40 to 60% restoration of viability at 1.5mM
NB7M depending on the inhibitor used) (Figure 4B).
In addition to the activation of pro-apoptotic kinases, NB7M
excerted inhibitory effects on various prosurvival kinases.
Immunoblotting experiments indicated that downregulation of
DNA-Pk and Axl expression in SKOV-3 cells upon NB7M
treatment occurred within 18h of treatment (Figure 4C) and
revealed a time-dependent downregulation of the activation/
phosphorylation of various prosurvival proteins such as PI-3k
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Figure 2 NB7M effect on cell growth in NCI60 cancer cell line screen. (A) NCI60 cell line in vitro screening at 10mM NB7M. Cells (see Supplementary
Information) were treated in 96-well plates with 10mM of NB7M or vehicle and cell viability of the TCA fixed treated and untreated cells assessed after 48h
with sulphorhodamine-B (SRB) solution and absorbance read at 515nM.( B) Dose-dependent effect of NB7M on ovarian cancer cells in NCI60 screen (see
(A) and Supplementary Information).
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s(phosphatidylinositol 3-kinase), Akt, IKKa and transcription
factor NF-kB (Figure 4D).
NB7M effect on cell proliferation and cell-cycle
progression
As described in the previous sections, NB7M is a cytotoxic agent
that activates apoptotic processes in SKOV-3 ovarian cancer cells.
To investigate if NB7M affects the proliferation of SKOV-3 cells
(particularly at drug concentrations when viability is not affected
or partially reduced), we performed a BrdU incorporation assay. In
this assay, BrdU incorporation into replicating DNA is detected
by an antibody–peroxidase conjugate allowing a colorimetric
reaction with the colour intensity directly representing cell
proliferation. NB7M dose-dependently reduced SKOV-3 prolifera-
tion (Figure 5A). At a drug concentration of 1.5mM (for 48h)
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Figure 3 NB7M causes apoptosis in SKOV-3 platinum-resistant ovarian cancer cells. (A) Membrane depolarisation analysis after NB7M treatment. SKOV-
3 cells were treated for 12 or 24h with 2mM NB7M, fixed and stained with DiOC6(3) as described (Materials and Methods). Fluorescence of the single-cell
population was measured by flow cytometry and the transmembrane depolarisation potential of the single-cell populations plotted. Ten thousand cells were
analysed in each sample. (B) Morphological changes following NB7M treatment. SKOV-3 cells were treated for 24h with 2mM NB7M, fixed and stained with
40-6-diamidino-2-phenylindole (DAPI) as described (Materials and Methods) before mounting. Microscopy was carried out (Nikon Eclipse TE2000-E
inverted microscope,  20 objective), and representative images were taken. Bar¼10mM.( C) Caspase activation following NB7M treatment. SKOV-3 cells
were treated with 2mM of NB7M for 1, 6, 18 or 36h. Analysis of the expression of proteins in the lysates of treated and untreated cells was carried out by
PAGE and western blot analysis as described (Material and Methods). Primary antibodies against activated caspases-3, -8, -9, and inactivated/cleaved PARP-1
were used. As an internal standard for equal loading, the blots were probed with an anti-b-actin antibody. (D) Effect of caspase inhibitors on SKOV-3 viability
following NB7M treatment. SKOV-3 cells were pre-incubated with specific inhibitor (40mM) against caspase-3 for 2h and treated with NB7M (0, 1 or 2mM)
in the continued presence of the inhibitors (40mM) for an additional 48h. The MTS viability assay was carried out as described (Materials and Methods).
Experiments were performed in triplicates; data are expressed as the mean of the triplicate determinations (X±s.d.) of a representative experiment in % cell
viability of samples with untreated cells. (E) TUNEL assay. SKOV-3 cells were treated with either 2mM of NB7M or 25mM of actinomycin D for 48h.
Labelling of DNA nicks with fluorescein-12-dUTP and chromatin counterstaining with propidium iodide was carried out as described (Materials and
Methods). Representative images were taken, apoptotic stain (FL-dUTP, green) and nuclear stain (Pi, red) overlaid; TUNEL-positive nuclei because of DNA
fragmentation appear as yellow areas. Bar¼10mM.
Cytotoxicity, signalling effects of NB7M in cancer cells
RK Singh et al
1827
British Journal of Cancer (2008) 99(11), 1823–1831 & 2008 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sproliferation of treated SKOV-3 was inhibited by 70% as
compared to untreated cells. Even at drug concentrations in the
nano-molar range BrdU incorporation into the DNA was reduced.
Thus, NB7M is a potent pro-apoptotic agent as well as an
antiproliferative agent.
Cell-cycle analysis of SKOV-3 cells after NB7M treatment
at subcytotoxic concentrations (250 and 500nM) revealed a
significant increase in the G1-phase cell population and reduction
in S-phase cells compared to untreated control, while the G2 cell
population remained largely unaffected within 18–36h of treat-
ment (Figure 5B and C). Interestingly, 6h of treatment temporarily
led to a decrease of cells in the G1-phase and an increase in
S-phase. This indicated that proliferation and S-phase progression
was adversely affected within 6h of treatment, while a block of
cell-cycle progression in G1 in this non-synchronised culture
unfolded within 18h of treatment. Immunoblotting revealed that
NB7M treatment of SKOV-3 affected the expression of two
prominent members of the Cip/Kip family of cyclin-dependent
kinase (CDK) inhibitors, which are key regulators involved in cell
growth in vivo, in vitro, in tumour and normal tissues (Stillman,
1996; Albrecht et al, 1998; Pines, 1999): P27 (kip1) CDK was
upregulated and p21 downregulated upon NB7M treatment
(Figure 5D). These preliminary observations suggest further
studies on the specific antiproliferative mechanisms of NB7M in
cancer cell lines (e.g., ovarian tumour).
DISCUSSION
NB7M is a novel synthetic indole ethyl ITC designed from 7Me-
IEITC, a potent cytotoxic agent in its own right (Singh et al, 2007,
2008). Unprotected indole nitrogen groups of 7Me-IEITC can
potentially cause chemical degradation reactions. Accordingly,
NB7M was synthesised by
tBoc-protection of the indole nitrogen of
7Me-IEITC; the addition of an acid-labile protecting group (tert-
butyl carbamate) on the secondary nitrogen is most likely to
enhance the stability of the indole ethyl ITC. We recently reported
that NB7M shows potent apoptotic and inhibitory effects on the
cell cycle in nervous system cancer cell lines (Brard et al, 2008).
In this study, the cytotoxicity of NB7M in well-characterised
human solid tumour cancer cell lines (ovarian, prostate, skin and
pancreas) and two human control cell lines with similar growth
rate (TCL-1/immortalised trophoblasts and HTR-8-SVneo/first-
trimester cytotrophoblasts with extended lifespan) was defined.
NB7M showed no adverse effect on TCl-1 and HTR-8 at a
concentration (5mM) that was highly cytotoxic to the five cancer
cell lines. Given the differential responses of controls versus cancer
cells tested, the effect of NB7M on cell growth was screened by the
NCI Developmental Therapeutics Program (DTP) against a panel
of 60 cancer cell lines, which broadly represent human tumours of
colon, ovarian, lung, melanoma, leukaemia, renal, prostate and
central nervous system. NB7M showed potent activity against most
Actin
P-NFκB
NFκB
P-IKKα
IKKα
P-Akt
Akt
P-PI3-K
PI3-K
36 h 18 6 0
NB7M 2 M
NB7M 2 M
NB7M 2 M
kD
85
85
60
60
85
85
65
65
42
NB7M concentration (M)
3 1.5 0
NB7M+SB202190
NB7M+SB203580
NB7M+SB202474
NB7M
0
15
30
45
60
75
90
105
C
e
l
l
 
v
i
a
b
i
l
i
t
y
(
%
 
o
f
 
u
n
t
r
e
a
t
e
d
 
c
o
n
t
r
o
l
)
Actin
Axl
DNA-pK
36 h 18 6 0 kD
450
138
42
Actin
JNK/SAPK
P-JNK/SAPK
p38
P-p38
ERK1/2
P-ERK1/2
42
46
54
46
54
43
43
44/42
44/42
kD 0 6 18 36 h
Figure 4 Expression of prosurvival markers and MAPKs in SKOV-3 following NB7M treatment; effect of MAPK inactivation on cell viability. (A) Activation
of MAPKs. SKOV-3 cells were treated with 2mM of NB7M for 6, 18 or 36h. Analysis of the expression of proteins in the lysates of treated and untreated cells
by PAGE and western blot analysis was carried out as described (Material and Methods), using primary antibodies against pro- and activated/phosphorylated
(P-) SAP/JNK, p38 and ERK1/2. As an internal standard for equal loading, the blots were probed with an anti-b-actin antibody. (B) Effect of p38 MAPK
inactivation on cell viability. SKOV-3 cells were pre-incubated with specific inhibitors (40mM) against p38 MAPK for 2h and treated with NB7M (0, 1 or 2mM)
in the continued presence of the inhibitors for an additional 48h. The MTS viability assay was carried out as described (Materials and Methods). Experiments
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and Axl proteins. (D) Inactivation of survival signalling proteins and transcription factor proteins: SKOV-3 cells were treated with 2mM of NB7M for 6, 18 or
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against pro- and activated/phosphorylated PI-3K, STAT-3, IKKa or NF-kB.
Cytotoxicity, signalling effects of NB7M in cancer cells
RK Singh et al
1828
British Journal of Cancer (2008) 99(11), 1823–1831 & 2008 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
stumour types. Notable exceptions were non-small cell lung cancer
cell subtypes NCI-H322H, HOP-62, EKVX and A549. The
compounds minimal activity against several non-small lung cancer
cells is reminiscent of data retrieved after the treatment by
naturally occurring ITCs (PEITC and BITC) causing cell death of
A549 non-small lung cancer cells only at higher doses (Fang and
Hwa, 2004). The cytotoxicity toward SKOV-3 ovarian cancer cells,
however, is several fold higher when NB7M is used instead of BITC
and PEITC (this study, Kalkunte et al, 2006; Satyan et al, 2006).
The DTP at the NCI maintains a public accessible database of
cytotoxic drugs; a comparison analysis (COMPARE) of known
cytotoxic drugs versus NB7M indicated that NB7M is more potent
than a variety of clinically relevant drugs, such as cisplatin,
oxaloplatin, seliciclib, CNDAC, 5-FU and cyclophosphamide, in
most of the NCI60 cell lines but is less potent than docetaxel,
adriamycin and gemcitabine.
Our in vitro investigations have shown that NB7M and its
synthetic parent compound 7Me-IEITC show overlapping cyto-
toxic effects with ovarian cancer cell lines OVCAR-3 and SKOV-3
being more sensitive to NB7M as compared to 7Me-IEITC (present
manuscript; Singh et al, 2008). This also applies to several
neuroblastoma cell lines, while the viability of lung fibroblasts or
trophoblast cell lines by either compound is only marginally
affected (Singh et al, 2007; Brard et al, 2008). These overlapping
effects are not surprising because 7Me-IEITC, due to conversion by
hydrolytic enzymes such as amidases, may be a metabolite of the
N4-protected NB7M, similar to conversion of N4-protected
sapacitabine into gemcitabine and ara-C in cancer cells (Serova
et al, 2007). Nevertheless, differences in the degree of cytotoxic
action by these related compounds could be explained by the
unique stereo-electronic properties of NB7M due to a carbamate
group not present in 7Me-IEITC, which may offer additional
interactions with target proteins. In addition, the introduction of a
tertiary butyl carbamoyl substituent of the indole nucleus of 7Me-
IEITC most likely endowed NB7M with resistance to intramole-
cular or intermolecular reactions (e.g., between the indole nitrogen
with the ITC group). Finally, the fact that cells may accumulate and
retain a higher concentration of NB7M (because it is more
lipophilic than 7Me-IEITC) might explain the differences in drug
cytotoxicity.
NB7M and its precursor 7Me-IEITC showed a striking similarity
in the expression and/or activation of a multitude of molecular
targets, including DNA-PK, Axl, PI-3K, Akt; the MAPKs ERK1/2,
p38, JNK; NF-kB and the CDK inhibitor p27 (present manuscript;
Singh et al, 2007; Brard et al, 2008; Singh et al, 2008). Many types
of tumours are associated with activated oncogenic kinases. These
kinases play two complementary roles; they stimulate signalling
pathways that enable cells to function independent of their
environment and they cause tumour cells to become resistant to
genotoxic therapies (Hanahan and Weinberg, 2000). For example,
Axl is known to bind the vitamin K-dependent protein growth-
arrest-specific gene 6 (Gas6) and to activate PI-3K and its
downstream targets S6K, Akt and NF-kB (Crosier and Crosier,
1997; Demarchi et al, 2001). The serine/threonine kinase, Akt, and
its family members are amplified or their activity is constitutively
elevated in human carcinomas such as breast, pancreatic, ovarian,
brain, prostate and gastric tumours (Nicholson and Anderson,
2002). Drugs such as NB7M that can block Akt, PI-3K, survival
kinase IKKa and transcription factor NF-kB activities, which are
known to contribute to tumour growth by promoting cell-cycle
entry, cell proliferation, cell migration, or antiapoptotic responses,
and are implicated in resistance to radio- and chemotherapy (Kip
et al, 2002; Greten and Karin, 2004), are potential cancer
therapeutics.
As it is a direct downstream target of PI-3K, Akt is a key
oncogenic survival factor and can inactivate a broad panel of
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scritical pro-apoptotic molecules such as p38 MAPK, Bad, caspase-9,
the Forkhead transcription factor FKHRL1, GSK3-b, cell-cycle
inhibitors p21 and p27, and tumour suppressors p53 and
TSC2 (Zhou et al, 2001; Inoki et al, 2002; Blain and Massague,
2002; Liao and Hung, 2003). Activation of Akt has been shown to
induce resistance to apoptosis induced by a number of drugs
(Page et al, 2000). Activation of the PI-3K/Akt pathway has been
linked to cisplatin resistance in ovarian cancer cell lines (Lee et al,
2005). Consequently, our observations that NB7M inactivates
the PI-3K pathway and downstream factors IKKa and NF-kB
suggests that NB7M could be used to enhance the effectiveness
of chemotherapy of drug resistant tumours. Several natural
compounds and synthetic drugs that are able to inhibit the IKK/
NF-kB activation pathway have been shown to either prevent
cancer or to inhibit cell growth in animal models (Bharti and
Aggarwal, 2002), and we suggest further exploration of potential
chemotherapeutic properties of NB7M in an ovarian cancer animal
model.
This report also shows that NB7M, in addition to its selective
cytotoxic properties, at subcytotoxic concentrations acts as a
potent inhibitor of SKOV-3 ovarian cancer cell proliferation.
NB7M treatment affects cell-cycle checkpoints in G1-phase,
causing reduction in the progression of cells into S- and G2/M-
phase. Blocking the progression of dividing cells to G2/M-phase
also reduces the possibility of DNA repair and thereby leads to
increased cell death, counteracting/bypassing resistance mecha-
nisms. Similarly, another plant-derived molecule, Guggulsterone,
caused cell-cycle arrest in S-phase by the suppression of cyclin D1
and cdc2 and increased CDK inhibitor p21 and p27 expression in a
wide variety of human tumour cell types (Shishodia et al, 2007).
Apparently, transformed cells can be more sensitive to CDK
inhibition because of the fact that components of the cell-cycle
machinery are frequently altered in human cancer (Hartwell and
Kastan, 1994; Gladden and Diehl, 2003), and thus, can be
specifically targeted. Even though not the objective of this report,
future studies will examine the effects of NB7M on specific cell-
cycle checkpoints in synchronised ovarian cancer cells. Targeting
cell-cycle checkpoints has been suggested as an alternative
approach to anticancer therapies (Shapiro and Harper, 1999;
Mazumder et al, 2004), and NB7M at subcytotoxic concentrations
has the potential to selectively interfere with the progression of
cancer cell proliferation.
In summary, this report suggests that NB7M is a potent growth-
suppressing agent to cell lines derived from ovarian cancers and a
potential therapeutic drug to treat such tumours in vivo.
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